Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
1. A bispecific antibody comprising: an anti-HER2 antibody comprising two heavy chains and two light chains and an anti-HER3 single chain antibody variable fragment (Fv) comprising a heavy chain variable domain and a light chain variable domain, wherein said Fv is linked to each of the two CH3 domains of the anti-HER2 antibody, wherein the light chain variable domain of the anti-HER3 single chain Fv comprises amino acid residues 607-717 of SEQ ID NO: 1 and the heavy chain variable domain of the anti-HER3 single chain Fv comprises amino acid residues 473-591 of SEQ ID NO: 1, wherein the light chain variable domain of the anti-HER2 antibody comprises amino acid residues 20-127 of SEQ ID NO: 2 and the heavy chain variable domain of the anti-HER2 antibody comprises amino acid residues 20-139 of SEQ ID NO: 1, and wherein the bispecific antibody facilitates formation of HER2-HER3 heterodimers and inhibits the growth or proliferation of a cancer cell when administered or applied at a therapeutically effective amount and in combination with a tyrosine kinase inhibitor.
2. The bispecific antibody of claim 1 , wherein the heavy chain of the anti-HER2 antibody is linked to a N′ terminus end of the single chain Fv.
3. The bispecific antibody of claim 1 , wherein the single chain Fv is linked to the CH3 domain by a linker comprising a Gly-Ser-Ser sequence.
4. The bispecific antibody of claim 1 , wherein the single chain Fv comprises a (Gly 4 Ser) n linker peptide between the heavy chain variable domain and the light chain variable domain.
5. The bispecific antibody of claim 1 , wherein the cancer cell is a SK-BR-3 cell or BT-474 cell or HCC1419 cell or other breast cancer cell, and the proliferation of the cancer cell is reduced by at least 25% relative to a control cell.
6. The bispecific antibody of claim 1 , wherein the bispecific antibody comprises a human antibody, a humanized antibody, or a chimeric antibody.
7. A composition comprising the bispecific antibody of claim 1 in a pharmaceutically acceptable carrier.
8. A method of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of the composition of claim 7 in combination with lapatinib or erlotinib to inhibit growth or proliferation of cancerous cells, wherein the subject is human and the cancerous cells express HER2 and HER3.
9. A method of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of a first agent comprising the bispecific antibody of claim 1 in combination with a therapeutically effective amount of a tyrosine kinase inhibitor, wherein the subject is human and the cancer expresses HER2 and HER3.
10. The method of claim 9 , wherein the tyrosine kinase inhibitor is lapatinib or erlotinib.
11. The method of claim 9 , wherein the tyrosine kinase inhibitor is selected from the group comprising a small molecule targeting IGF1R, a small molecule targeting EGFR, a small molecule targeting ErbB2, a small molecule targeting cMET, an mTOR inhibitor, and an MEK inhibitor.
12. The method of claim 8 , wherein the composition and lapatinib or erlotinib are administered simultaneously.